Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Glioblastoma RNAseq in TTFields-treated samples

ABSTRACT: TTFields Glioblastoma

PROVIDER: PRJEB56095 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

TTFields treatment effects on newly diagnosed Glioblastoma patients in peripheral T lymphocytes

Project description:We report the application of RNA-based sequencing technology for high-throughput profiling of T cell enriched peripheral blood mononuclear cells. By sequencing in total of 12 pairs GBM patient samples, we extracted TCRαβ V(D)J sequences from the deep RNA-seq of T cells isolated from the 24 PBMCs to determine if TTFields treatment affected TCR diversity, using the Simpson’s diversity index (DI), which is the average proportional abundance of TCR clones based on the weighted arithmetic mean. Of the 12 patients, 9 exhibited negative log fold change (logFC) of TCR DI after TTFields, indicating clonal expansion. Notably, in all but 1 patient, the top 200 most abundant clones post TTFields, which accounted for 38.1% to 100% (median 67%) of detectable clones, showed substantial expansion compared to pre-TTFields T cells, and inversely correlated with the DI. Thus, TTFields treatment is associated with adaptive immune activation as evidenced by clonal expansion of peripheral T cells.

2022-04-20 | GSE193729 | GEO

RNA-seq of pancreatic cell lines AsPC1 and BxPC3 treated with Tumor Treating Fields (TTFields) compared to control samples

Project description:This study investigates the preclinical effects of Tumor Treating Fields (TTFields) in pancreatic ductal adenocarcinoma (PDAC).

2025-12-30 | E-MTAB-15132 | biostudies-arrayexpress

PTEN homozygous deletion is a negative prognostic factor in Tumor Treating Fields-treated glioblastoma, IDH wildtype patients

Project description:DNA methylation profiling of glioblastoma, IDH-wildtype (GBM, IDH wt) to explore biomarkers linked to clinical outcome under Tumor Treating Fields (TTFields). FFPE tumor tissue was pathology-reviewed and macro-dissected; DNA was bisulfite-converted and hybridized to Illumina Infinium MethylationEPIC BeadChips (v1.0 and v2.0). The submission provides raw IDATs. Methylation classes and copy-number profiles were derived and integrated with clinical covariates to test whether (epi-) genetic features stratify prognosis and can guide TTFields initiation.

2025-12-04 | E-MTAB-16255 | biostudies-arrayexpress

Monitor the dynamic changes of GBM cell lines under TTFields treatment

Project description:We used 3 established GBM cell lines to generate TTFields-resistant cells using Inovitro system.

2024-10-08 | GSE270513 | GEO

TTFields treatment effects on newly diagnosed Glioblastoma patients in peripheral T lymphocytes

Project description:TTFields treatment effects on newly diagnosed Glioblastoma patients in peripheral T lymphocytes

| PRJNA797422 | ENA

TTFields plus TMZ treatment effects on newly diagnosed Glioblastoma patients in peripheral blood

Project description:We report the application of single-cell-RNA-based sequencing technology for high-throughput profiling of peripheral blood mononuclear cells. By sequencing in total of 193,760 PBMCs in 12 GBM patients, we generated an overview of patient peripheral immune status with 38 biologically recongnized cell subtypes. By paired comparing pre- and post- treatment samples, we find a robust post-TTFields activation of adaptive immunity via the T1IFN trajectory anchored by plasmacytoid DCs. This study provides a framework for the application of scRNAseq towards characterization of peripheral immune activation status.

2025-01-01 | GSE193525 | GEO

TTFields plus TMZ treatment effects on newly diagnosed Glioblastoma patients in peripheral blood

Project description:TTFields plus TMZ treatment effects on newly diagnosed Glioblastoma patients in peripheral blood

| PRJNA796536 | ENA

RNAseq Analysis in glioblastoma cells treated with Mepazine

Project description:Glioblastoma cells were treated with vehicle (DMSO) or mepazine (MPZ, 20 μM, 4 hours) and prepared for RNAseq according to ActiveMotif standard procedure. The list of differentially expressed genes from DESeq2 output was selected based on 10% adjusted p-value level and FDR of 0.1.

2019-10-18 | GSE139018 | GEO

RNAseq Analysis in glioblastoma cells treated with Mepazine

Project description:RNAseq Analysis in glioblastoma cells treated with Mepazine

| PRJNA578094 | ENA

Gene expression analysis of electrical therapies on glioblastoma cell lines

Project description:The scarcity of effective treatment options for high grade brain tumours has led to a wide ranging search for alternative means of therapy for these difficult to treat tumours. Electrical field therapy is one such area that has been considered. The OptuneTM system is an FDA approved novel anti-mitotic device that delivers continuous alternating electric fields to the patient for the treatment of primary and recurrent Glioblastoma multiforme (GBM) (tumor treating fields - TTFields). Alternative electric fields delivery systems are also being investigated for the treatment of various cancers.To further explore alternative potential mechanisms of electric fields as a whole, we ran Optune, DBS electric fields treated and control untreated KNS42, U87 and GIN-31 (primary) cell lines on Clariom S Human Assays to produce genome-wide expression data.

2020-10-01 | E-MTAB-9043 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data